Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Biogen Idec reports higher Q3 net income, provides annual outlook

Biogen Idec Inc., a biotechnology company, has reported that net income attributable to the company for the third quarter ended September 30, 2014 was $856.86 million, or $3.62 per diluted share, compared to $487.62 million, or $2.05 per diluted share, for the same quarter ended September 30, 2013. For 2014, the company expects GAAP diluted EPS to be between $12.00 and $12.10, and non-GAAP diluted EPS to be between $13.45 and $13.55.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Invacare reports net loss for Q3

Invacare Corporation, a manufacturer of medical equipment, has reported that net loss for the third quarter ended September 30, 2014 were $15.1 million, or $0.47 loss per share, compared to net earnings of $16.1 million, or $0.50 per share, for the same quarter ended September 30, 2013.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

BioMarin Pharmaceutical reports net income for Q3, updates Q4 guidance

BioMarin Pharmaceutical Inc. has reported that net income for the third quarter ended September 30, 2014 was $7.44 million, or $0.05 per share, compared to a net loss of $53.02 million, or $0.38 loss per share, for the same quarter ended September 30, 2013. For fourth quarter of 2014, the company expects total revenues to be in the range of $700 to $710 million, compared to the prior guidance of $680 to $700.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Merck receives breakthrough therapy designation from FDA for lung cancer drug

Merck & Co., Inc. has received breakthrough therapy designation from the FDA for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of patients with epidermal growth factor receptor, or EGFR, mutation-negative, and anaplastic lymphoma kinase, or ALK, rearrangement-negative non-small cell lung cancer, or NSCLC, whose disease has progressed on or following platinum-based chemotherapy.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Ipsen and Lexicon sign licensing agreement for carcinoid syndrome treatment

Ipsen, a specialty pharmaceutical company, and Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

AirStrip and IBM partner to develop new mobile monitoring solution

AirStrip, a provider of clinical mobility solutions, and International Business Machines Corporation, or IBM, have announced that AirStrip will develop a mobile monitoring solution using IBM's streaming analytics technology to help clinicians predict declining health in acute and critically ill patients.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Allscripts partners with ScriptSave for new prescription savings program

Allscripts, a provider of healthcare information technology solutions, has partnered with ScriptSave, a provider of prescription savings solutions, to deploy capabilities that can promote patient adherence.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Epizyme announces resignation of chief medical officer

Epizyme, Inc., a clinical stage biopharmaceutical company, has announced the resignation of Eric Hedrick as chief medical officer, effective October 31, 2014.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

PerkinElmer launches imaging system for cancer immunology research

PerkinElmer, Inc., a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets, has launched Mantra Quantitative Pathology Workstation with inForm Image Analysis Software for cancer immunology and immunotherapy research.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Vermillion appoints COO

Vermillion, Inc., a diagnostics company focused on gynecologic cancers and women's health, has appointed Valerie Palmieri to the newly created role of COO, reporting directly to CEO James LaFrance.

Published By MarketLine
29 Oct 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.